AlphAIAlphAI — Financial news for AI agents
qz.comSEP 292 min read

Oura postpones Nasdaq IPO amid market uncertainty

Oura postponed its Nasdaq IPO, targeting $2.2B from 50M shares at $40-$44 each, valuing it at $15.62B. CEO Tom Hale cited market conditions. Oura reports 90% revenue growth expected for 2026, 5.7M paid members, and profitability. Investors like Eli Lilly and Dragoneer showed interest. Goldman Sachs, Morgan Stanley, and J.P. Morgan are underwriters.

Original reporting
qz.com
Published Sep 29, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 12:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oura postpones Nasdaq IPO amid market uncertainty — source image
Source · qz.com
Decision brief

The 30-second read

High
01

Why it matters

The postponement removes immediate supply of new shares, likely reducing short‑term volatility in related fintech and wearable stocks.

02

Market read

The delay underscores heightened sensitivity of IPO markets to macro‑economic headwinds, affecting investor appetite for new listings.

03

What to watch

Oura's strong revenue growth and profitability could attract renewed interest once market conditions improve.

Relevance 8/10Novelty 8/10Timing: today

Background

Oura, a health‑monitoring wearable maker, had filed for a Nasdaq IPO targeting a $15.6 B valuation but postponed the offering due to market uncertainty.

Market effects

Sector

IPO postponement may signal broader weakness in tech listings amid rate uncertainty.

Regional

Potential dampening effect on US Nasdaq new‑issue pipeline and related fintech investors.

Global

Highlights macro‑driven slowdown in capital markets affecting both US and European issuers.

Counterpoint

What could challenge this read

Some investors may view the delay as a temporary pause, positioning for a later, potentially higher‑priced offering.

Key entities

  • company
    Oura

    Finnish health‑tech firm planning a Nasdaq IPO.

  • underwriter
    Goldman Sachs

    Lead underwriter for Oura's planned IPO.

Read at source← All news

Also covered by

5 outlets

Related articles

SEP 30
MedAI 8/10

Smart Ring Maker Oura Delays Nasdaq IPO, Citing Market Uncertainty

Oura, a smart ring maker, delayed its Nasdaq IPO citing market uncertainty. The company aimed to sell 50M shares, raising up to $2.2B at a $15B valuation. Oura reported strong earnings, with $907.8M revenue and $23.5M pretax profit in fiscal 2025. The delay follows a lawsuit alleging false advertising, but the company denies this influenced the decision.

en.sedaily.com2 min
SEP 30
Low

Oura postpones its $2.2bn IPO, citing market uncertainty

Oura postponed its $2.2bn IPO, citing market uncertainty despite strong demand. It planned to sell 50M shares at $40-$44 each. The company is profitable, with 5.7M paid members and expects 90% revenue growth in 2026. Four companies postponed IPOs in the same week, according to Renaissance Capital.

thenextweb.com2 min
SEP 30
Low

Smart ring maker Oura postpones anticipated IPO

Oura, a smart ring maker, delayed its Nasdaq IPO due to market uncertainty, despite strong growth and profitability. The company reported $1.21 billion in revenue for the nine months ending in June, up 74% year-over-year, and plans 90% growth for its 2026 fiscal year. Oura had aimed to raise $2.2 billion at a $15 billion valuation, with 50 million shares priced between $40 and $44 each.

massdevice.com1 min
SEP 30
LowAI 8/10

Oura Postpones Nasdaq IPO Despite Rapid Growth

Oura postponed its Nasdaq IPO, citing market uncertainty, despite strong demand and revenue growth. The company planned to offer 50M shares at $40-$44, potentially raising $2.2B. Oura reported $1.21B revenue for the first nine months of 2026, up 74% YoY, with net income rising from $1.6M to $60.8M. The company aims to become a preventative-health platform, but faces competition and legal challenges.

boxrox.com3 min